MAPT and Alzheimer disease: Therefore, the identification of rapamycin as a systemic treatment for protecting lateral perforant pathway neurons and synapses from tau-mediated degeneration has implications for therapeutic strategies attempting to slow the progression of AD at multiple stages of disease.